About Us

Neurodyn Cognition Inc. is a spin-out company of Neurodyn Life Sciences Inc. – a special purpose company established to commercialize Memogain®

MemogainRender2 copy



  • A next generation pro-drug of an approved AD drug (Reminyl)
  • Alpha-7 potentiation – main mechanism
  • No side effects, high brain delivery
  • Potent disease modification demonstrated pre-clinically
  • Potential rapid EU approval



Get the latest on Neurodyn Cognition from CEO, Kenneth Cawkell, in this feature presentation at Noble Capital Markets’ 14th Annual Investor Conference.